There are currently 314 clinical trials in Norfolk, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Hospital of the King's Daughters, Virginia Oncology Associates, Sentara Norfolk General Hospital and Eastern Virginia Medical School. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
NCT05816382
Recruiting
The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
09/24/2024
Locations: Children's Specialty Group, Norfolk, Virginia
Conditions: Narcolepsy Type 1
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Neuroblastoma
Register for Updates
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/21/2024
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Neuroblastoma
Register for Updates
EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy
NCT05476276
Recruiting
This is a Platform Protocol to perform Phase II clinical trials in The Early Phase Pain Investigation Clinical Network (EPPIC-Net), under The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, related to the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) in a platform setting to test multiple assets under a single protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: Eastern Virginia Medical School, Norfolk, Virginia
Conditions: Painful Diabetic Neuropathy
Register for Updates
Child and Adolescent Registry for Participants With Narcolepsy
NCT04899947
Recruiting
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com.... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
08/13/2024
Locations: Children's Hospital of the King's Daughters, Norfolk, Virginia
Conditions: Narcolepsy
Register for Updates
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
NCT02670707
Recruiting
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body,... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/01/2024
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert
NCT06087913
Recruiting
MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for 14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand method for prevention of HIV and HSV sexual infection.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
07/26/2024
Locations: Eastern Virginia Medical School Clinical Research Clinic (EVMS CRC), Norfolk, Virginia
Conditions: Safety Issues
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Virginia Oncology Associates - Lake Wright, Norfolk, Virginia +1 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Multi-analyte Blood Test Clinical Trial
NCT05199259
Recruiting
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Digestive & Liver Disease Specialist, Norfolk, Virginia
Conditions: Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
Register for Updates
Eliminating Monitor Overuse Trial (EMO Trial)
NCT05132322
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Bronchiolitis Acute Viral
Register for Updates
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
NCT05313165
Recruiting
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
05/31/2024
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Register for Updates
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
NCT04474223
Recruiting
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Eastern Virginia Medical School (EVMS), Norfolk, Virginia
Conditions: AVB - Atrioventricular Block, Fetal AVB
Register for Updates